Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 451-455

  Alberts, David S ^a   Blessing, John A ^b   Landrum, Lisa M ^c   Warshal, David P ^d   Martin, Lainie P ^e   Rose, Stephen L ^f   Bonebrake, Albert J ^g   Ramondetta, Lois M ^h  

^a UNIVERSITY OF ARIZONA   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d Department of Anesthesiology   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g Ozark Health Ventures LLC   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cervix cancer; Drug resistant cervix cancer; GOG; Nab paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; UTERINE CERVICAL NEOPLASMS;

EID: 84868597108     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.09.008     Document Type: Article

References (20)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics CA Cancer J Clin 61 2011 212 236
2. W.P. McGuire, J.A. Blessing, D. Moore, S.S. Lentz, and G. Photopulos Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study J Clin Oncol 14 1996 792 795
3. P.G. Rose, J.A. Blessing, D.M. Gershenson, and R. McGehee Paclitaxel and cisplatin as a first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 17 1999 2676 2680
4. W.J. Gradishar Albumin-bound paclitaxel: a next-generation taxane Expert Opin Pharmacother 2006 1041 1053
5. J.P. Micha, B.H. Goldstein, C.L. Birk, M.A. Rettenmaier, and J.V. Brown III Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions Gynecol Oncol 100 2006 437 438
6. D.W. Nyman, K.J. Campbell, E. Hersh, K. Long, U. Richardson, and V. Trieu Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J Clin Oncol 23 2005 7785 7793
7. I.C. Henderson, and V. Bhatia Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy Expert Rev Anticancer Ther 7 2007 919 943
8. G. Dranitsaris, R. Coleman, and W. Gradishar Nab-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial Cancer Res Treat 119 2010 717 724
9. W.J. Gradishar, D. Krasnojan, S. Cheporov, A.W. Makhson, G.M. Marikhas, and A. Clawson Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 2009 3611 3619
10. B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of Bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study J Clin Oncol 27 2009 1069 1074
11. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumors. Revised RECIST guideline (version1.1) Eur J Cancer 45 2009 228 247
12. T.T. Chen, and T.H. Ng Optimal flexible designs in phase II clinical trials Stat Med 17 1998 2301 2312
13. P.K. Paik, L.P. James, G.J. Riely, C.G. Azzoli, V.A. Miller, and K.K. Nq A phase 2 study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion Cancer Chemother Pharmacol 68 2011 1331 1337
14. A.D. Santin, P.L. Hermonat, A. Ravaggi, S. Percorelli, M.J. Cannon, and G.P. Parham Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix Obstet Gynecol 94 1999 78 82
15. I.J. Lee, K.R. Park, K.K. Lee, J.S. Song, K.G. Lee, and J.Y. Lee Prognostic value of vascular endothelial growth factor in Stage 1B carcinoma of the uterine cervix Int J Radiat Oncol Biol Phys 54 2002 768 779
16. K.S. Tewari, and B.J. Monk Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer Curr Oncol Rep 7 2005 419 434
17. P.G. Rose, J.A. Blessing, and J. Arseneau Phase II evaluation of altretamine for advanced and recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Gynecol Oncol 62 1996 100 102
18. M.A. Bookman, J.A. Blessing, P. Hanjani, T.J. Herzog, and W.A. Anderson Topotecan in squamous cell carcinoma of the cervix. A phase II Gynecologic Oncology Group study Gynecol Oncol 77 2000 446 449
19. P.G. Rose, J.A. Blessing, M. Morgan, L. Van Le, and S. Waggoner Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Gynecol Oncol 70 1998 263 266
20. R. Schlider, J.A. Blessing, M. Morgan, C.E. Mangan, and J.S. Rader Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group study Gynecol Oncol 76 2000 204 207